Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Menthol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 known ✓ | Q7Z2W7 | 5/20 | 1.00 |
| ▸ | TRPA1 known ✓ | O75762 | 2/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Menthol SCHEMBL10072505 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| (+)-Menthol SCHEMBL15449169 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| Isomenthol SCHEMBL677675 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| Racementhol SCHEMBL521946 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| (+)-Menthol SCHEMBL9968934 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| (+)-Menthol SCHEMBL1709231 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| (+) Neomenthol SCHEMBL260049 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| (+)-Menthol SCHEMBL12646785 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| Menthol SCHEMBL20771511 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 | |
| (+)-Menthol SCHEMBL2454317 | 1.00 | TRPM8 (1.00) | TRPM8TRPA1EPHX1ALDH1A1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109851608-A | A kind of preparation method of indole-2-carboxylic acid ester | 中国科学院兰州化学物理研究所 | 2019-06-07 | — | — | CN | disclosed |
| US-10028920-B2 | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 | UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) | 2018-07-24 | — | — | US | disclosed |
| US-10028920-B2 | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 | UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) | 2018-07-24 | — | — | US | disclosed |
| US-9901549-B2 | Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists | UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) | 2018-02-27 | — | — | US | disclosed |
| US-9662286-B2 | Composition of menthol and menthyl lactate, its preparation and its use as a cooling, flavouring and/or fragrance agent | BASF SE (DE) | 2017-05-30 | — | — | US | disclosed |
| US-20170071875-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) | 2017-03-16 | — | — | US | disclosed |
| US-20170071875-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) | 2017-03-16 | — | — | US | disclosed |
| US-20170049728-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) | 2017-02-23 | — | — | US | disclosed |
| US-20170049728-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) | 2017-02-23 | — | — | US | disclosed |
| US-9433679-B2 | Use of TRMP8 for treating opthalmic diseases or conditions involving tearing | UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) | 2016-09-06 | — | — | US | disclosed |
| US-9095609-B2 | Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia | UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) | 2015-08-04 | — | — | US | disclosed |
| US-9095609-B2 | Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia | UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) | 2015-08-04 | — | — | US | disclosed |
| US-20130245231-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) | 2013-09-19 | — | — | US | disclosed |
| US-20130245231-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) | 2013-09-19 | — | — | US | disclosed |
| US-7842687-B2 | Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration | CHEMGENEX PHARMACEUTICALS, INC. (AU) | 2010-11-30 | — | — | US | disclosed |
| US-7842687-B2 | Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration | CHEMGENEX PHARMACEUTICALS, INC. (AU) | 2010-11-30 | — | — | US | disclosed |
| EP-1768943-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | IND TECH RES INST (CN) | 2008-12-17 | — | — | EP | disclosed |
| US-7432383-B2 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE-SERIPHARM (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028920-B2 | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885TRPA1 12/4885EPHX1 1020/4885 |
| US-20170049728-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885TRPA1 22/4885EPHX1 1393/4885 |
| US-20170071875-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885TRPA1 22/4885EPHX1 1393/4885 |
| US-20130245231-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885TRPA1 22/4885EPHX1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.